What Merck & Co., Inc. reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 310158 · Filed Nov 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 14M |
| ±0% |
| $228.7M |
| 27.9% |
KYMRKymera Therapeutics, Inc. | 772.2K | ±0% | $86.3M | 10.5% |
AKTSAktis Oncology, Inc. | 952.8K | ±0% | $18.6M | 2.3% |
EIKNEikon Therapeutics, Inc. | 1.7M | ±0% | $13.4M | 1.6% |
TRDAEntrada Therapeutics, Inc. | 1.7M | ±0% | $11M | 1.3% |
ALECAlector, Inc. | 3.5M | ±0% | $6.6M | 0.8% |
STROSutro Biopharma, Inc. | 272.4K | New | $4.4M | 0.5% |
EVAXEvaxion A/S | 1.2M | ±0% | $4M | 0.5% |
VRDNViridian Therapeutics, Inc.DE | 93.4K | ±0% | $1.9M | 0.2% |
XLOXilio Therapeutics, Inc. | 106K | ±0% | $959.1K | 0.1% |
HURATuHURA Biosciences, Inc. | 19.4K | ±0% | $40.8K | 0.1% |
NEUPNeuphoria Therapeutics Inc. | 10K | ±0% | $35.7K | 0.1% |